Ulrich Lehner - Novartis AG Insider

NVSN -- Mexico Stock  

MXN 1,570  0.00  0.00%

  Chairman
Prof
Age: 68  Chairman Since 2006  MBA    
41 61 324 1111  http://www.novartis.com
Ulrich Lehner, Ph.D., was Vice Chairman of the Board of Directors and NonExecutive Director of Novartis AG since 2006. He serves as Chairman of the Corporationrationrationrate Governance and Nomination Committee of the Company, as well as Member of the Audit and Compliance Committee, the Risk Committee, the Chairman?s Committee, and the Compensation Committee. He has acted as NonExecutive Director and Member of the Board of Directors of the Company since 2002. He has also cowoorked with the Audit Committee. From 1975 to 1981, he was an auditor with KPMG Deutsche TreuhandGesellschaft AG in Duesseldorf. In 1981, he joined Henkel KGaA. After heading the Controlling Department of Fried. Krupp GmbH in Germany from 1983 to 1986, Prof. Lehner returned to Henkel as Finance Director. From 1991 to 1994, he headed Henkel AsiaPacific Ltd in Hong Kong, and from 1995 to 2000, served as Executive Vice President, Finance/Logistics, of Henkel KGaA. From 2000 to 2008, Prof

Management Efficiency

The company has return on total asset (ROA) of 4.65 % which means that it generated profit of $4.65 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 11.62 % meaning that it generated $11.62 on every $100 dollars invested by stockholders.
The company has accumulated 34.11 B in total debt with debt to equity ratio (D/E) of 47.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novartis AG has Current Ratio of 1.15 suggesting that it may not be capable to disburse its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG operates under Drug Manufacturers - Major classification in Mexico and traded on Mexico Stock Exchange. It employs 124000 people.Novartis AG (NVSN) is traded on Mexico Stock Exchange in Mexico. It is located in Lichtstrasse 35 and employs 124,000 people.

Novartis AG Leadership Team

Joerg Reinhardt, Chairman of the Board
Ton Buechner, Non-Executive Independent Director
Paul Hudson, CEO of Novartis Pharmaceuticals, Member of the Executive Committee
Verena Briner, Non-Executive Independent Member of the Board
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Head of HR
Dimitri Azar, Member of the Board of Directors
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Enrico Vanni, Member of the Board of Directors
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Erwin Vanhaecke, Head Novartis Group Quality
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Michael Ball, CEO of Alcon, Member of the Executive Committee
Elizabeth Barrett, CEO, Novartis Oncology
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Member of the Board of Directors
Joseph Jimenez, CEO, Member of the Executive Committee
Samir Shah, Global Head Investor Relations
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Ann Fudge, Member of the Board of Directors
Srikant Datar, Member of the Board of Directors
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, CFO
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now
   

Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Portfolio Anywhere

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">